Results 301 to 310 of about 1,468,461 (396)

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source

Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions

Cancer Innovation, Volume 4, Issue 4, August 2025.
Glioblastoma (GBM) remains a highly malignant brain tumor with limited treatment efficacy, driving the need for innovative cellular immune theranostic strategies that integrate diagnostic and therapeutic approaches. Recent advances in cellular immunotherapy for GBM include chimeric antigen receptor (CAR)‐T/NK cells, macrophage‐based therapies ...
Ying Gong, Wanying Lin, Xuechun Fang, Ruyi Zhang, Min Luo, Haoran Wu, Shuai Chu, Chuangkun Li, Yiming Peng, Zhiyan Piao, Siping Wu, Junhao Li, ZongZhong He, Haixia Li, Hongxia Wang   +14 more
wiley   +1 more source

Nuclear Imaging of Bispecific Antibodies on the Rise. [PDF]

J Nucl Med
Roohani B, Mendez AS, Dangarwala M, Katz S, Marquez-Nostra B.   +4 more
europepmc   +1 more source

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

, 2012
Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer Haas, Markus Uhrberg   +9 more
openalex   +1 more source

Multidisciplinary assessment of patients with extensive stage small cell lung cancer: A geriatric tumor board

CA: A Cancer Journal for Clinicians, EarlyView.
Humera Khurshid, Sakeena Raza, Robert Brunault, Brittany Duffy, Michael Kavanaugh   +4 more
wiley   +1 more source

Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database

Cancer Medicine, Volume 14, Issue 15, August 2025.
ABSTRACT Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease. Methods We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide‐refractory MM using data from Optum
Binod Dhakal, Hermann Einsele, Jordan M. Schecter, William Deraedt, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Sandhya Nair, Nirosha Elsem Varghese, Jianming He, Akshay Kharat, Seina Lee, Patricia Cost, Ravi Potluri, Mythili Koneru, Nitin Patel, Erika Florendo, Paula Rodriguez‐Otero, Kwee Yong   +18 more
wiley   +1 more source

Sequencing bispecific antibodies and CAR T cells for FL. [PDF]

Hematology Am Soc Hematol Educ Program
Russler-Germain DA, Bartlett NL.
europepmc   +1 more source

Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 × Anti-CMV Bispecific Antibody

, 2012
Lawrence G. Lum, Mayur Ramesh, Archana Thakur, S. Mitra, Abhinav Deol, Joseph P. Uberti, Philip E. Pellett   +6 more
openalex   +1 more source

Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

CA: A Cancer Journal for Clinicians, EarlyView.
Lauren J. Antrim, Jyoti Malhotra
wiley   +1 more source

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 418-427, August 2025.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj, Dmitry Shchelokov, Oleg Demin Jr, Homer C. Adams 3rd, Yan Feng, Leonid Gibiansky, Saskia van der Lee, Anandhi Johri, Merzu Belete, Alexander Muik, Porntula Panorchan, Özlem Türeci, Uğur Sahin, Tahamtan Ahmadi, Manish Gupta, Oleg Demin, Craig Thalhauser   +16 more
wiley   +1 more source